Liu Zi-Ning, Yang Xiao
Laboratory of Pathophysiology, Shandong Second Medical University, Weifang, Shandong 261053, P.R. China.
Department of Neurorehabilitation, Shengli Oilfield Central Hospital, Dongying, Shandong 257000, P.R. China.
Oncol Lett. 2025 Aug 21;30(5):493. doi: 10.3892/ol.2025.15239. eCollection 2025 Nov.
The incidence and mortality rates of tumors continue to show an annual upward trend. Since its discovery in 1986, nuclear receptor subfamily 2, group F, member 2 (NR2F2) has been shown to serve a key role in the transcriptional regulation of various genes. Furthermore, NR2F2 has a notable impact on the progression of tumors; however, its role in tumor progression it not yet fully understood. Multi-omics can illuminate the paradoxical roles of NR2F2 across various malignancies, where it functions as either an oncogenic driver or tumor suppressor in a context-dependent manner. The present review discusses the determinant influence of NR2F2 in modulating disease advancement and mechanisms in heterogeneous types of cancer, including its effects on tumor proliferation, apoptosis and epithelial-mesenchymal transition. The aim was to assess the role and mechanisms of NR2F2 in various tumors, identify its clinical utility in targeted cancer therapy and thereby provide a novel therapeutic option for overcoming cancer.
肿瘤的发病率和死亡率持续呈现逐年上升的趋势。自1986年被发现以来,核受体亚家族2、F组成员2(NR2F2)已被证明在多种基因的转录调控中发挥关键作用。此外,NR2F2对肿瘤进展具有显著影响;然而,其在肿瘤进展中的作用尚未完全明确。多组学能够阐明NR2F2在各种恶性肿瘤中的矛盾作用,在不同背景下它既可以作为致癌驱动因子,也可以作为肿瘤抑制因子。本综述讨论了NR2F2在调节疾病进展中的决定性影响以及在不同类型癌症中的作用机制,包括其对肿瘤增殖、凋亡和上皮-间质转化的影响。目的是评估NR2F2在各种肿瘤中的作用和机制,确定其在靶向癌症治疗中的临床应用价值,从而为攻克癌症提供一种新的治疗选择。